Cargando...

Clinical trials of CAR-T cells in China

Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Hematol Oncol
Autores principales: Liu, Bingshan, Song, Yongping, Liu, Delong
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651613/
https://ncbi.nlm.nih.gov/pubmed/29058636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0535-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!